Despite encountering a legal roadblock last month in his effort to rework the U.S. vaccine infrastructure, HHS secretary ...

Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the ...

Charles River Laboratories has backed an American Heart Association (AHA) campaign, joining forces with the nonprofit on ...

Takeda ended its neurogenerative disease partnership with Denali Therapeutics. Merck & Co. and Zhifei have scrapped a minimum ...

Amneal and BioCorRx have earned the ire of the FDA’s Office of Prescription Drug Promotion (OPDP), with both being hit by ...

Novartis is making further workforce reductions at its U.S. headquarters in New Jersey, planning to remove 114 positions as ...

Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear look at which ...

As geopolitics bring reshoring interest to a fever pitch, the United States Pharmacopeia (USP) is adding to the impetus for ...

Envision Pharma Group has hired clinical research veteran Nick Jones as president of its Envision Medical Communications (EMC ...

AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount ...

In connection with the deal, Assertio has divested the rest of its assets to New Jersey generics and branded drugmaker ...

Japan’s Shionogi is joining the spate of drugmakers to announce manufacturing commitments in the U.S. since last year, albeit ...